Equipment sharing among people who inject drugs (PWID) is a key risk factor in infection by hepatitis C virus (HCV). Both the effectiveness and cost-effectiveness of interventions aimed at reducing HCV transmission in this population (such as opioid substitution therapy, needle exchange programs or improved treatment) are difficult to evaluate using field surveys. Ethical issues and complicated access to the PWID population make it difficult to gather epidemiological data. In this context, mathematical modelling of HCV transmission is a useful alternative for comparing the cost and effectiveness of various interventions. Several models have been developed in the past few years. They are often based on strong hypotheses concerning the popula...
Hepatitis C virus (HCV) is a blood-borne infection that can lead to progressive liver failure, cirrh...
Equipment sharing among injecting drug users (IDUs) is a key risk factor in infection by hepatitis C...
Hepatitis C virus (HCV) is the second largest contributor to liver disease in the UK, with injecting...
Equipment sharing among people who inject drugs (PWID) is a key risk factor in infection by hepatiti...
Injecting drug users (IDUs) are the largest risk group for HCV infection. Studying injecting by clas...
The discovery of highly effective hepatitis C virus (HCV) treatments has led to discussion of elimin...
This article discusses two models, with two different needle assumptions for the transmission of hep...
In order to prevent the spread of the hepatitis C virus (HCV) amongst people who inject drugs (PWID)...
With the development of new highly efficacious direct acting antiviral treatments (DAAs) for hepatit...
Background: The hepatitis C virus (HCV) epidemic is a major health issue; in most developed countrie...
Hepatitis C virus (HCV) chronically infects over 180 million people worldwide, with over 350,000 est...
Background: Highly effective direct-acting antiviral (DAA) regimens (90% efficacy) are becoming avai...
Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological ...
Hepatitis C virus (HCV) infection remains a major health problem despite the availability of highly...
Hepatitis C virus (HCV) is a blood-borne infection that can lead to progressive liver failure, cirrh...
Equipment sharing among injecting drug users (IDUs) is a key risk factor in infection by hepatitis C...
Hepatitis C virus (HCV) is the second largest contributor to liver disease in the UK, with injecting...
Equipment sharing among people who inject drugs (PWID) is a key risk factor in infection by hepatiti...
Injecting drug users (IDUs) are the largest risk group for HCV infection. Studying injecting by clas...
The discovery of highly effective hepatitis C virus (HCV) treatments has led to discussion of elimin...
This article discusses two models, with two different needle assumptions for the transmission of hep...
In order to prevent the spread of the hepatitis C virus (HCV) amongst people who inject drugs (PWID)...
With the development of new highly efficacious direct acting antiviral treatments (DAAs) for hepatit...
Background: The hepatitis C virus (HCV) epidemic is a major health issue; in most developed countrie...
Hepatitis C virus (HCV) chronically infects over 180 million people worldwide, with over 350,000 est...
Background: Highly effective direct-acting antiviral (DAA) regimens (90% efficacy) are becoming avai...
Dynamic modelling of hepatitis C virus transmission among people who inject drugs: a methodological ...
Hepatitis C virus (HCV) infection remains a major health problem despite the availability of highly...
Hepatitis C virus (HCV) is a blood-borne infection that can lead to progressive liver failure, cirrh...
Equipment sharing among injecting drug users (IDUs) is a key risk factor in infection by hepatitis C...
Hepatitis C virus (HCV) is the second largest contributor to liver disease in the UK, with injecting...